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Implementation of CE-MS identified proteome based biomarker panels in drug development 2 
and patient management 3 
Abstract 4 
The recent advancements in clinical proteomics enabled identification of biomarker panels 5 
for a large range of diseases. A number of CE-MS identified biomarker panels were verified 6 
and implemented in clinical studies. Despite multiple challenges, accumulating evidence 7 
supports the value and the need for proteome-based biomarker panels.  8 
In this perspective, we provide an overview of clinical studies indicating the added value of 9 
CE-MS biomarker panels over traditional diagnostics and monitoring methods. We outline 10 
apparent advantages of applying novel proteomic biomarker panels for disease diagnosis, 11 
prognosis, staging, drug development and patient management. Facing the plethora of 12 
benefits associated with the use of CE-MS biomarker panels, we envision their 13 










Defined key terms 22 
Clinical proteomics: Sub-discipline of proteomics concerned with application of proteomic 23 
technologies on clinical specimens to obtain information on protein networks and the 24 
identification of protein-based biomarkers. Urine and blood, due to their minimally invasive 25 
method of collection, are the most commonly used body fluids for clinical proteomics. 26 
 “Humanised” biomarker panels: Biomarker panels composed of multiple molecules that are 27 
orthologous (share sequence similarity) between human and animals. Such humanised 28 
biomarker panels are of high value for translational medicine. 29 
Personalized medicine: Medical approach for disease treatment and prevention that takes into 30 
account biological differences and variations among individuals, in order to develop the best 31 
suited for a given individual therapy. Biomarker panels facilitate the personalized medicine 32 
approach by pointing the individual differences between patients. 33 
Patient stratification: Process of subdividing patients into groups differing in terms of 34 
biological make up and expected clinical response. Patient stratification is a common 35 
concept in clinical trials, which aims to select the optimal population for drug evaluation. As 36 
an example, implementation of biomarker panels in nephrology allows patient stratification 37 
with greater accuracy than commonly used methods based on functional parameters such as 38 
albuminuria and estimated glomerular filtration rate. 39 
Omic platforms: High throughput platforms encompassing proteomics, metabolomics, 40 
genomics, and transcriptomics allowing the analysis of the global molecular content of a 41 





Drug development and patient management are crucial to any healthcare system. These two 45 
aspects are interconnected and influence each other. One of the best examples of their 46 
mutual dependence is the development of the personalised medicine approach, which aims 47 
to deliver “the right drug at the right dose to the right patient” [1]. The concept of 48 
personalised medicine was already evident to Hippocrates (460 – 370 BC), who apparently 49 
said: “It’s far more important to know what person has the disease than what disease the 50 
person has”.   51 
Essentially all drugs either directly or indirectly target the function of specific proteins. Along 52 
the same lines: any pathophysiologic change (that will ultimately result in a specific disease) 53 
is associated with and dependent on specific changes on the protein level (Figure 1). 54 
Therefore, protein-based biomarkers appear to be best suited to inform about disease, the 55 
optimal treatment options, and drug effects on patients subjected to therapies [2]. In 56 
contrast, histological assessment (e.g. in tissue biopsies) can inform about structural 57 
damage, but generally holds no information on molecular pathophysiology or the respective 58 
drug targets.   59 
A state of an organism (healthy or diseased) relies on the interplay among different 60 
biological levels (genomics, transcriptomics, proteomics, and metabolomics). Proteomics, 61 
defined as the analysis of the total protein content of a sample or system, is a prominent 62 
multiparametric approach, providing information beyond what genomics or transcriptomics 63 
can deliver. When describing the different omics platforms an analogy to a fireplace can be 64 
made (Figure 2)[3]. Genomics could be considered as the logs of wood, containing all 65 
potential, but no information about actual execution. However, it can be assessed fairly well 66 
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and accurately. Proteomics can be considered as a fire, integrating the potential with the 67 
environmental impact. It is highly variable, difficult to assess in detail, but contains all 68 
information about the current status. Metabolomics is analogous to the ashes, representing 69 
the result of the fire (protein) action, clearly containing information about the action of the 70 
fire and thus potentially leading to the identification of metabolite-based biomarkers of 71 
disease, but most likely not representing active or early disease stages. In addition, any 72 
interference targeting the ashes would generally be too late to be of relevance in the 73 
context of the fire. 74 
Irrespective of the omics-trait, combination of multiple biomarkers has shown to have 75 
improved performance (specificity and sensitivity) over single biomarkers [4]. This appears to 76 
be a result of compensating for the biological variability generally associated with any 77 
biomarker. This variability can be counteracted either by multiple measurements of the 78 
same biomarker, or by the simultaneous measurement of multiple markers. The latter has 79 
the additional value that bias that may be associated with a single biomarker, even if 80 
measured repeatedly, can be corrected for by the additional markers that generally should 81 
not display an identical bias.  82 
These observations have resulted in the development of multi-marker panels and classifiers. 83 
While initially such classifiers were flawed as a result of data overfitting [3,5], and due to 84 
inadequate technology and data interpretation, these issues have been addressed in several 85 
guidance manuscripts [6,7].  Hence, the implementation of omics-based biomarker panels 86 
into the clinical practice, drug development, and patient management, becomes more 87 
feasible every day. 88 
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In this perspective, we discuss the value and consequence, but also technical issues 89 
associated with the implementation of multi-biomarker panels into the medical practice in 90 
the near future, either to complement or to replace currently used standards. This 91 
assumption is based on the growing evidence demonstrating the advantages of biomarker 92 
panels over currently applied traditional tools.  93 
Proteomic platforms in biomarker research 94 
Different proteomics platforms are currently employed, the most common ones are LC-MS, 95 
2DE-MS, and CE-MS. The pros and contras of the different platforms have been described in 96 
detail in several recent reviews [8-11]. In Table 1 the main advantages and disadvantages of 97 
the most common techniques are listed. The high complexity of the mammalian proteome 98 
imposes the need for pre-fractionation prior to mass spectrometry (MS) analysis e.g. by 99 
using two-dimensional gel electrophoresis (2DE), liquid chromatography (LC) or capillary 100 
electrophoresis (CE). The separation phase is coupled to a mass spectrometer, either on- or 101 
off-line. 2DE-MS has the advantage over the other techniques of obtaining additional 102 
information on the full protein such as molecular mass and isoelectric points. The major 103 
drawback of 2DE-MS is its low throughput and low resolution compared to other 104 
technologies. Shot-gun LC-MS is most often used for discovery studies and displays high 105 
resolution. The comparison of LC and CE-MS indicated that small and highly charged 106 
molecules are rather unable to bind to the LC column, but can be detected with CE-MS [12]. 107 
Due to the long run-times (often 4-8 h to obtain high resolution) LC-MS has rather low-108 
throughput and was found less robust and reproducible than CE-MS in direct comparison 109 
[12,13]. Further comparison between LC and CE-MS did not reveal a big difference in the 110 
variation in migration time and peak area repeatability (these need to be corrected for both, 111 
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CE and LC-MS). Yet, LC-MS is more commonly used than CE-MS in research. This appears at 112 
least to some degree due to the fact that no vendor currently offers a complete working CE-113 
MS solution fit for clinical application. However, CE-MS has demonstrated its value in 114 
biomarker discovery and validation, the by far largest proteomics studies (including >10 000 115 
subjects, [14]) reported are based on CE-MS, CE-MS is used in PRIORITY, the currently largest 116 
clinical proteomics study including over 3200 subjects ([15], NCT02040441,) and it is used in 117 
clinical decisions. 118 
MRM (multiple reaction monitoring), targeting multiple protein-based biomarkers in 119 
complex samples, is a promising LC-MS-based alternative for ELISA and is specifically used in 120 
biomarker validation studies. It is high-throughput and allows absolute quantification. It is 121 
however due to the use of peptides standards still costly. CE-MS is focussing on native 122 
peptides and due to its reproducibility and comparability between datasets can be used for 123 
discovery, validation and clinical application.  124 
 125 
The combination of the separation phase with high-resolution mass spectrometers enables 126 
to theoretically resolve over 1 million compounds. Irrespective of the approach used, the 127 
platform and the utilized protocols have to be well-characterized in the context of analytical 128 
variability and measurement precision, prior to the implementation of the analytical strategy 129 
[6]. 130 
Table 1. Main proteomic approaches applied in the field of biomarker research.  
Approach Advantages Disadvantages Application  Other characteristics 
2DE-MS 
Retains Information 
at protein level 
Low throughput and 
low resolution 
Biomarker discovery Enables relative quantification 
7 
 
LC-MS (shot-gun) High resolution Low throughput Biomarker discovery 
Data analysis is often complex; 
currently the most widely used 










Promising alternative to ELISA for 
targeted quantification 
CE-MS 








Established technology for a wide 
range of urinary-peptide-profiling 
applications; clinical 
implementation feasible 
Abbreviations: CE-MS, capillary electrophoresis coupled to mass-spectrometry; 2DE-MS, 2-dimensional gel electrophoresis 
followed by mass-spectrometry; LC-MS, liquid chromatography coupled to mass-spectrometry.  
Adapted with permission from [8] (C) Nature Publishing Group (2015). 131 
 132 
Capillary electrophoresis coupled mass spectrometry (CE-MS) technology and its clinical 133 
application 134 
CE-MS has been applied in clinical proteomics for over 10 years and enabled identification of 135 
multiple proteomic-based biomarker panels [3,16]. Capillary electrophoresis can be 136 
hyphenated to a number of MS technologies including time of flight (TOF), ion-traps 137 
(Orbitraps) and triple quadrupoles mass spectrometers [17,18]. However CE-ESI-(electron 138 
spray ionization)-TOF has been the most widely used approach and the only one currently 139 
contributing to patient management. This may be owed to the TOF representing the optimal 140 
compromise between resolution and sensitivity, versus cost. We will therefore in the 141 
remainder of review focus on CE-ESI-TOF (for convenience called CE-MS in the rest of the 142 
manuscript). Over time, CE-MS method was demonstrated to be a powerful analytical tool 143 
for the identification, characterization and quantification of protein and peptide biomarkers 144 
in urine. The work flow involving the CE-MS technology with associated computational 145 
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approach is depicted on Figure 3. The sample preparation and the CE-MS analytical cycle are 146 
performed according to a standardised protocol enabling good reproducibility and 147 
comparability, also when urine samples of other species are to be analysed [19]. In the 148 
typical standard procedure, 700 µL of urine are defrosted with the addition of 0.1% PMSF 149 
saturated in ethanol and diluted with 700 µL of a solution containing 2 M urea, 10 mM 150 
NH4OH and 0.02% SDS. The mixture is filtered through a 20 kDa MW cut-off 151 
ultracentrifugation filter device (Sartorius Stedim UK Ltd, United Kingdom) at 3,000 rcf for 152 
one hour at 4°C. A volume of 1.1 mL of the filtrate is subsequently loaded onto a PD-10 153 
desalting column (GE Healthcare, Sweden) pre-equilibrated with 0.01% aqueous NH4OH. The 154 
eluate is then freeze-dried and stored at 4°C prior to being resuspended in HPLC-grade water 155 
to a final protein concentration of 2 mg/mL for CE-MS analysis. For CE, typically 250 nl of a 156 
sample are injected hydrodynamically in a 90 cm long fused silica capillary of 75 µm inner 157 
diameter, which is filled with running buffer containing 79:20:1 (v/v) MilliQ water, 158 
acetonitrile, formic acid. Peptides are separated in an electric field of 300 V/cm. The capillary 159 
temperature is set to 35°C for the entire length of the capillary up to the ESI interface.  160 
Different interfaces between CE and ESI have been described in greater detail elsewhere 161 
[20]. 162 
The MS analysis is performed in positive electrospray mode using e.g. a microTOF-MS 163 
(Bruker Daltonic, Bremen, Germany). The ESI sprayer is grounded and the ion spray interface 164 
potential is set between 4 and 4.5 kV. The sheath liquid is applied coaxially at a rate of 200 165 
nL/min. The data acquisition and the MS method are automatically controlled by the CE 166 
program via contact-close relays. Spectra are accumulated every 3 s, over an m/z range from 167 
400 to 3000 for 60 min.  CE-MS enables high throughput screening (1000-6000 analytes per 168 
sample) with high analytical specificity and sensitivity for small (< 20 kDa) proteins or 169 
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peptides (hence it is frequently referred to as a peptidomics approach) from biological fluids 170 
(mainly urine) or tissue supernatants [16]. The method is relatively fast (an analytical cycle 171 
takes approximately 60 min and sample preparation can be accomplished in 8 hrs), simple 172 
and reproducible. A standardised protocol and a set of peptides used for internal 173 
normalization contribute to the good reproducibility of the method [21,22]. The main clinical 174 
application was, and still is, in the assessment of the urinary proteome/peptidome. Urine 175 
appears to be especially well suited for clinical application, as the urine 176 
proteome/peptidome displays much higher stability than blood [2] . This is probably due to 177 
the fact, that urine before collection is “residing” in the bladder for several hours, where it 178 
exposed to 37oC and to a number of proteolytic enzymes [3]. A major shortcoming is the 179 
variability in the protein and peptides concentrations arising as a result of fluctuations in 180 
daily fluid intake, circadian rhythms, and physical activity. These variations can be 181 
compensated by the use of various normalizing methods [23]. 182 
Several studies performed comparison of CE-MS with other proteomics technologies. When 183 
investigating chronic kidney disease (CKD), 273 peptides associated with CKD could be 184 
detected with CE-MS, while only three were found with MALDI-MS [24,25]. A direct 185 
comparison between CE-MS and MALDI-MS revealed better performance and greater 186 
reproducibility of CE-MS than MALDI-MS in CKD diagnosis [10].  In the utilised experimental 187 
set up, examining the peptidome of urine, a biologically and clinically relevant sample, CE-188 
MS displayed superior resolution, robustness, and reproducibility, and lower variability, in 189 
comparison to LC-MS [26]. A disadvantage of CE-MS is its low loading capacity, which may 190 
impact on the assessment of very low abundant proteins and peptides.  However, when 191 
comparing different platforms, CE-MS is currently the only technology that can be employed 192 
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for biomarker discovery, validation, and clinical application. This contrasts with LC-MS, which 193 
requires a change in technology (additional steps, such as multiple reaction monitoring 194 
(MRM) or antibodies) for validation or clinical application after the discovery phase. 195 
Furthermore, CE-MS is delivering tens of thousands of comparable datasets and thereby is 196 
greatly facilitating the evaluation of newly discovered biomarkers in closely related diseases 197 
for the assessment of the true specificity of “disease-related” biomarkers. In total, the 198 
approach has been used to date in over 50 different disease etiologies involving over 35 000 199 
independent samples [101]. An overview of the different diseases investigated and the 200 
number of datasets available is presented in Figure 4. This database represents a highly 201 
valuable resource, as it enables comparative assessment (based on highly reproducible 202 
sample preparation and analytical technology) of multiple peptides in tens of thousands of 203 
datasets [101]. Finally, it is also the only proteome-based technology applied to studies with 204 
over 10000 subjects [14].  205 
Proteome-based biomarker discovery with the CE-MS technology is a rapidly expanding area. 206 
Especially urinary proteomics is penetrating the field of clinical diagnostics, as urine is easily 207 
accessible and collected, available in large quantities, and of higher stability than other body 208 
fluids (blood, plasma, serum, or cerebrospinal fluid). Not surprising, the main application is 209 
in the field of nephrology. A literature search with keywords in Web-of Science with TOPIC: 210 
"capillary electrophoresis" AND "mass spectro*" OR CE-MS AND TOPIC: proteom* AND 211 
TOPIC: marker OR biomarker (DOCUMENT TYPES: ARTICLE OR REVIEW) over the timespan 212 
2010-2015 yielded 125 manuscripts, with 91 related to renal disease. The CE-MS urinary 213 
proteomic approach enabled the discovery of at least 17 biomarker panels for 214 
diagnosis/prognosis of many common as well as rare diseases (Table 2) [16]. Several of these 215 
CE-MS-based biomarker panels are already registered and in use for clinical diagnosis in 216 
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Europe. Based on one urinary CE-MS analysis, multiple diseases can be assessed via 217 
application of designated biomarkers, enabling early detection and prediction of disease 218 
development several years in advance. For example:  219 
• a classifier based on 273 urinary peptides “CKD273” was identified in the context of 220 
human chronic kidney diseases (CKDs) from different aetiologies (diabetic 221 
nephropathy (DN), IgA nephropathy, ANCA-associated vasculitis, focal segmental 222 
glomerulosclerosis, membranous glomerulonephritis, minimal change disease, and 223 
lupus nephritis) [25]. Subsequently this classifier was assessed for its predictive value. 224 
Several studies demonstrated that it allows: i) early detection of CKD or DN [27,28], 225 
with greater accuracy than the current clinical functional parameters (urinary 226 
albumin or plasma creatinine levels) and ii)  prediction of CKD evolution from 227 
moderate to end-stage renal disease (ESRD)[29]. This biomarker is currently the most 228 
accurate biomarker for prediction of CKD progression, as it correlates with estimated 229 
glomerular filtration rate (GFR) decline (eGFR slope/year (%)), a standard measure 230 
reflecting renal function decline, to a greater extent than urinary albumin [30]. In a 231 
recent systematic review the performance of CKD273 is outlined in detail [31], 232 
• heart failure (HF) biomarkers were identified using CE-MS based urinary proteomics 233 
and used to predict left ventricular dysfunction in asymptomatic hypertensive 234 
patients, indicating an advantage of implementing this approach as a screening 235 
method, prognostic tool and for subsequent monitoring purposes of individuals at 236 
risk [32],  237 
• CE-MS identified biomarker panels allowed to assess the risk of coronary artery 238 
disease (CAD) [33]. In addition, these biomarkers indicated a beneficial effect of 239 
dietary products like polyphenols or olive oil [34,35]. 240 
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Interestingly, the CE-MS studies for discovery and validation of urinary biomarkers also 241 
indicated that assessment of chronic conditions such as CKD or coronary artery disease 242 
(CAD) may require biomarkers comprised of a wider range of peptides than acute diseases 243 
such as acute kidney injury (AKI) or preeclampsia, further underscoring the complexity of 244 
chronic conditions [36-38].  245 
 246 






























Diabetic nephropathy (DN) 65 97 97 Rossing et al. [39] 
Chronic kidney disease (CKD) 273 86 100 Good et al. [25,27-30] 
ANCA-associated Vasculitis 18 90 90 Haubitz et al. [40] 
IgA Nephropathy 25 90 90 Julien et al. [41]  
Autosomal polycystic kidney 
disease (ADPKD) 
142 88 98 Kistler et al. [42] 
Acute kidney injury (AKI) 20 89 82 Metzger et al. [37] 
Posterior urethral valves (PUV) 12 88 95 Klein et al. [43] 
Ureteropelvic junction obstruction 
(UPJ) 





















Coronary artery disease 
15 98 83 Zimmerli et al. [45] 
17 81 92 von Zur Muhlen et al. 
[46]  
238 79 88 Delles et al. [47] 
35 56 93 Dwanson et al. [48] 
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Heart Failure (Left ventricular 
dysfunction) 
85 69 94 Kuznetsova et al. [32] 




































Acute graft versus host disease 
(aGvHD) grade III and IV 
31 83 77 Weissinger et al. [50] 
Acute renal allograft rejection 14 93 78 Metzger et al. [51] 
Bladder cancer (BCa) 22 100 63 Theodorescu et al. [52] 
Renal cell carcinoma (RCC) 86 80 87 Frantzi et al. [53] 
Prostate cancer 12 91 69 Theodorescu et al. [54] 
Cholangiocellular carcinoma 42 83 79 Metzger et al. [55] 
 248 
CE-MS identified biomarker panels for drug research and development in preclinical 249 
studies 250 
Preclinical animal models: Although animal models are frequently used in preclinical 251 
research, the translatability of results obtained in animal disease models to human is low, 252 
contributing to the high attrition rate of clinical trials investigating new drugs [56]. The 253 
availability of CE-MS identified biomarker panels for renal and cardiovascular diseases has 254 
great potential to improve on the selection of animal models for human disease. CE-MS 255 
analysis comparing the urinary proteome of humans and the Zucker diabetic fatty (ZDF) rat 256 
showed that this model does not reflect human DN on a molecular level [57], although 257 
routinely used as a model for this purpose. However, the ZDF rat model displays overlaps 258 
with human cardiovascular disease (CVD) biomarkers and may therefore be well suited for 259 
studying the CVD complications related to DN. Similarly, CE-MS analysis-based comparison 260 
of the urinary proteome of wild type (C57BL/6) mice harboring long term metabolic 261 
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syndrome with data on human DN indicated the absence of DN in this mouse model. Indeed, 262 
the renal injury in these mice with long-term metabolic syndrome induced by a high fat and 263 
fructose diet (HFFD) was minimal after 8 months of HFFD, as determined by detailed analysis 264 
of kidney structure and function utilizing GFR measurements and electron microscopy [58]. 265 
 266 
“Humanised” biomarker panels: These above mentioned studies indicate that CE-MS can be 267 
employed to assess the similarity of animal models and human disease. To close the gap 268 
between the preclinical and clinical stage and improve translation of results into the clinic, 269 
the CE-MS technology in combination with in silico models offers a simple yet effective 270 
solution: disease biomarker panels based on peptides orthologous between animal model 271 
and humans, ignoring the non-human animal disease related peptides. Observation in 272 
mouse models based on these “humanized” biomarker panels will have a great translational 273 
value. Recently such humanized biomarkers were identified using urinary peptidome data 274 
sets from two mouse models of type 2 diabetic (T2D)-DN and the human urinary proteome 275 
database. The identified orthologous biomarker panel for T2D-DN is more sensitive to reflect 276 
renal lesions in the investigated models than commonly used markers to detect renal injury, 277 
and this biomarker panel can be employed to assess benefit of therapeutic intervention in 278 
these preclinical mouse models (Schanstra et al., unpublished observations). In addition to 279 
the translational character of such humanized molecular models, the non-invasive character 280 
of the test allows on-route adjustment of drug concentrations and protocol lengths and thus 281 
contribute to the reduction in the number of animals required for experiments and thereby 282 




Safety and toxicity: Another promising area for implementation of biomarker panels is in the 285 
safety/toxicity tests of lead compounds in preclinical studies. A plethora of drugs are known 286 
to induce renal damage and for this reason their administration has to be in certain cases 287 
discontinued [59]. Therefore the detection of nephrotoxic effects of the lead compounds in 288 
the premarketing, ideally even in the preclinical stage, is of great importance to ensure that 289 
only selected, most promising compounds reach the market and do not have to be 290 
withdrawn, because of adverse effects on the kidney.  291 
Nephrotoxicity is an especially troubling issue for antibiotics, as they belong to the top ten 292 
medications, which damage the kidney [60]. Since the development pipeline for antibiotics 293 
was rejuvenated with recent initiatives encouraging their discovery (summarized elsewhere 294 
[102]), there is a growing need for nephrotoxicity tests for lead compounds with antibiotic 295 
properties. Implementation of the CE-MS technology for early detection of toxicity, already 296 
in preclinical stage, would enable the selection of nephrotoxicity-free compounds to enter 297 
the clinical studies on humans. Biomarker panels identified with CE-MS technology have 298 
demonstrated substantial potential for the determination of nephrotoxicity in animal models 299 
[61,62]. 300 
 301 
CE-MS identified biomarker panels in clinical studies: drug development and patient 302 
management 303 
Drug development is becoming increasing complex, and most candidates never reach the 304 
market. For example, only 10% of oncological drugs that enter clinical development reach 305 
the stage of market approval and 9 out of 10 candidates do not complete the process for 306 
market authorisation, mainly because no therapeutic benefit could be demonstrated or as a 307 
result of unfavourable side effects [63]. The use of biomarker panels could improve the drug 308 
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development process not only at the above mentioned preclinical level, but also in early- 309 
and late-stage clinical trials. 310 
 311 
Patient stratification: (urinary) biomarker panels could support selection and stratification of 312 
the trial population, and enriching for expected responders. Such approaches were first 313 
implemented in certain types of cancer, based on the availability of predictive biomarkers to 314 
detect aberrant gene expression products, affecting single genes (e.g. EGFR, HER-2, KIT, and 315 
BRCA1/BRCA2) or occurring due to gene fusion (eg. BCR-ABL), which drive the oncogenic 316 
phenotype [64-66]. In complex chronic diseases, such as renal or cardiovascular disease, 317 
single biomarkers or single gene mutations do not allow predicting the future disease course 318 
with high confidence. These diseases are heterogeneous in their pathophysiological and 319 
molecular background, thus require classifiers composed of multiple biomarker to account 320 
for their complexity and to provide a reliable measure of the severity of the pathological 321 
state. As demonstrated in several recent manuscripts, urinary biomarkers do not only allow 322 
assessing these diseases at an early stage, and enable prognosis, but they, as expected, also 323 
allow detection of the effects of therapeutic intervention [67]. For example, in diabetic 324 
nephropathy, irbesartan (angiotensin II receptor antagonist) initially developed for the 325 
treatment of hypertension, has been shown to delay progression of DN [68]. In a study with 326 
CE-MS- identified biomarkers for CKD, the renoprotective effects of irbesartan in 327 
microalbuminuric type 2 diabetic patients were clearly reflected in change of the pattern 328 
and score of the urinary biomarker panel for CKD [69]. Similarly, in the study of irbesartan in 329 
CAD patients, the CE-MS identified CAD biomarker pattern and overall score was significantly 330 
affected following two year treatment [47]. In another recent study, a significant beneficial 331 
17 
 
effect of olive oil consumption on cardiovascular disease (as assessed by CE-MS-based 332 
biomarkers) could be demonstrated [35]. 333 
Based on these results, the PRIORITY (Proteomic prediction and Renin angiotensin 334 
aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic 335 
patients with normoalbuminuria, PRIORITY, NCT02040441) study was initiated [15]. The 336 
study design, as depicted in Figure 5, aims at stratification of T2D patients for those that will 337 
develop CKD, using the well established CKD273 biomarker panel [25]. Patients positive in 338 
CKD273 screening will be randomized to low dose spironolactone (aldosterone antagonist) 339 
treatment or placebo. This large scale multicentric study in 13 different European centers 340 
aims at recruiting 3280 patients. If positive, this study will not only further demonstrate the 341 
predictive potential of the CKD273 classifier, but also the value of clinical proteomics in 342 
guiding early intervention. 343 
 344 
Risk stratification: The data available also indicate that the CE-MS identified biomarker 345 
disease panels (Table 2) can be employed for monitoring (side) effects of novel drugs in 346 
clinical trials. As an example, we would like to highlight several recent trials in the context of 347 
CKD where an increase in mortality in the treatment group raised substantial concerns. 348 
Bardoxolone initially showed promising results (increased eGFR) in patients with T2D kidney 349 
disease [70,71].  However, already within the first four weeks after randomization in a phase 350 
3 study (BEACON trial), the bardoxolone methyl group patients revealed a significant 351 
increase in hospitalization and death from heart failure [72]. Two years later post hoc 352 
analysis revealed that this was due to patients in the bardoxolone methyl treated group 353 
displaying an increased risk for heart failure already at the beginning of the trial [73,74]. This 354 
risk could have been assessed with CE-MS based urinary biomarkers a priori; patients 355 
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harbouring a signature for HF could have been excluded, and a potential benefit of 356 
bardoxolone could have been demonstrated. Similarly, in the Roadmap trial no convincing 357 
benefit, but a significant increase in mortality was observed [75]. Applying CE-MS analysis 358 
would not only have enabled enriching the population developing CKD (and hence likely 359 
demonstrating a convincing significant benefit), but also allowed excluding those patients 360 
that have an unfavorable risk profile (e.g. that are positive for CAD in the CE-MS based urine 361 
proteome analysis). The Altitude trial (NCT00549757) aimed at demonstrating a benefit of 362 
aliskiren, an aldosterone antagonist, as an add-on therapy to an angiotensin-converting-363 
enzyme inhibitor or an angiotensin-receptor blocker [76] However, the trial was stopped, as 364 
a result of lack of efficacy, and safety issues. As above, in this trial application of urinary CE-365 
MS analysis could have enabled stratifying for patients that would benefit from aliskiren 366 
intervention in a personalized/targeted medicine approach. 367 
Collectively these trials can be seen as a classical example for displaying the unmet need for 368 
proper risk stratification, especially if translation of the findings from preclinical to clinical 369 
stage becomes problematic due to lack of suitable animal models. In case of bardoxolone, 370 
the results of the experiments in the investigated animal models did not indicate potential 371 
harmful effects of this compound on the cardiovascular system [77]. The experimental data 372 
obtained from the rat model of T2D kidney disease (ZDF rat) indicated absence of a benefit 373 
on kidney function and negative impact on liver. Yet, the effects observed in the human 374 
bardoxolone methyl trial were completely different. This is likely owed to the fact that the 375 
ZDF rat does not appear to be a suitable model for human DN , hence the observed impact 376 




New study endpoints: Despite the increasing prevalence of CKD, there are fewer clinical 379 
trials investigating the effect of drugs on CKD progression than in other common diseases 380 
[78]. In January 2014, out of overall 4726 trials in medicine only 13 investigated DN, a 381 
leading cause of CKD across the world [79]. A reason may be the necessity of prospective 382 
studies with long follow-up periods to reach the currently accepted hard clinical endpoints 383 
(i.e. doubling of serum creatinine, end-stage renal disease (ESRD), or death) [68,80]. To 384 
improve on the management of CKD and stimulate clinical trials in the area, there is 385 
increased interest in exploring alternative clinical trial endpoints. In 2014, the European 386 
Medicines Agency (EMA) proposed that the primary efficacy endpoints for compound testing 387 
should be the prevention or delay of renal function decline defined as either time to 388 
occurrence or incidence rate of CKD stage 3 (eGFR 30-59 mL/min/1.73 m2) or higher, with or 389 
without prevention of proteinuria/albuminuria [103]. The efficacy of focusing on such 390 
shorter-term targets in CKD is supported by a recent meta-analysis including 1.7 million 391 
participants where it was concluded that a 30% reduction in estimated glomerular filtration 392 
rate (eGFR) over two years was strongly and consistently associated with the risk of ESRD 393 
and mortality [81,82]. The CE-MS identified biomarker panel, CKD273, enables prognosis of a 394 
class change to CKD stage 3, as demonstrated in a prospectively collected cohort of over 395 
1600 individuals [83]. Thereby, it is to our knowledge to date the only available biomarker 396 
panel to facilitate clinical trials with CKD stage 3 as a primary efficacy endpoint for 397 
compound testing, as proposed by EMA [103]. Drugs interfering with disease at an early 398 
stage (aim of the PRIORITY study) have a greater chance to prevent or slow down the 399 
progression of disease, as they can intervene with the molecular pathways governing the 400 
disease very early in disease development, before structural irreversible damage to the 401 
organs occurs. Biomarkers, such as CKD273 identified with CE-MS, are currently the only 402 
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means to evaluate drugs acting on asymptomatic CKD patients (e.g. PRIORITY), because such 403 
biomarkers reflect pathophysiological changes on the protein level in the course of disease 404 
and therefore are outcompeting the conventionally used/applied methods based on 405 
functional parameters (a significant reduction in eGFR, typical at and after CKD stage 3, 406 
reflects structural adverse alterations in the kidney).  407 
 408 
CE-MS technology and biomarker panels meet patient needs, open a window of 409 
opportunities for pharmaceutical industry and reduces work load of health care 410 
professionals, while increasing patient compliance 411 
 412 
Early diagnosis=improved outcome for patients: Use of the CE-MS technology has led to the 413 
discovery of protein-based biomarker panels that allow early detection of acute and chronic 414 
diseases. The major chronic diseases (e.g. diabetes, cardiovascular disease, kidney disease) 415 
are conventionally detected when symptoms appear (Figure 6). Unfortunately, at this point, 416 
in the majority of the cases the disease can already be qualified as advanced disease largely 417 
reducing the success of pharmacological treatment (e.g. a hypertrophied glomerulus in the 418 
kidney cannot be regenerated). At this late stage, disease progression can possibly only be 419 
delayed to some extend, although with moderate success, as also evident by the multiple 420 
trials that failed. For example most patients reaching CKD stage 3 will progress to a more 421 
advance stage and, in parallel, likely develop cardiovascular complications, leading to a 422 
significant reduction of the overall quality of life [82,84-86]. The option of accurate early 423 
disease detection also represents new opportunities for pharmaceutical and food industry as 424 
it enables earlier intervention and overall longer time-span for individuals to maintain high 425 
quality of life and healthy aging by providing adequate, ideally side-effects-free medication 426 
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due to the potential lower doses employed in early stage disease. Proteome analysis with 427 
CE-MS technology enables the identification of several diseases at an early stage, where 428 
intervention may still even be curative. Based on the individual CE-MS risk profile, 429 
personalized therapeutic approaches, that may well include dietary or lifestyle changes, 430 
could be implemented to enable “healthy ageing” [14].  431 
 432 
Benefits for health care professionals and on patients’ compliance: The implementation of 433 
non- or minimally-invasive biomarker panels in the clinical routine carries the advantage of 434 
enabling earlier detection, frequently with higher accuracy than the current state-of-the art, 435 
and without the risks associated with interventional procedures, hence will also increases 436 
patient compliance. For example, in case of bladder cancer, the very high recurrence rate 437 
has resulted in patients typically undergoing repeated cystoscopy for surveillance [8]. During 438 
this procedure, which is highly unpleasant and requires local or general anaesthesia, urethral 439 
damage can occur, despite being performed by trained physicians. Subsequently patients 440 
may experience urinary incontinence, occasionally local abdominal pains, and suffer from 441 
infection. In addition to being obtained invasively, this approach is dependent on a trained 442 
physician and subject to observer bias. In contrast, biomarkers panels lack this observer 443 
variability and lead to quantitative and highly comparable results. CE-MS-based biomarker 444 
panels have been developed for the management of bladder cancer [87]. While urinary 445 
proteomics may not fully replace the conventional invasive methods in diagnosis, it likely will 446 
guide their application towards only those patients with a very high risk, similar to 447 
stratification of patients for intervention. This will increase patient quality-of-life and 448 
compliance and is predicted to be cost-effective [8,88]. This potential cost effectiveness is 449 
related to the fact that the biomarker panels can provide not only information about 450 
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presence or absence of the disease, but also its status and thereby exclude expensive 451 
procedures (magnetic resonance imaging, computed tomography) performed to e.g. 452 
determine metastasis in patients that have no risk of harbouring metastases.  453 
A similar benefit is evident in managing prostate cancer (PC) [88]. The biomarker panel-454 
guided diagnosis of PC can increase patients compliance, as it can prevent trans-rectal 455 
ultrasound (TRUS) guided prostate biopsy, performed in patients with high levels of prostate 456 
specific antigen (PSA) in the blood, a conventionally used parameter for PC diagnosis [89].  457 
Since high PSA levels may also result from inflammation, age, sexual activity, and benign 458 
prostate hyperplasia [90-92], biomarker panels have a great potential to supplement the 459 
shortcomings of PSA determination as well [93].  460 
 461 
Conclusion 462 
The CE-MS technology has been used as a reproducible approach on over 35 000 human 463 
urine samples to date. It provided a large number of protein-based body-fluid biomarker 464 
panels for a wide variety of diseases, most of which have been validated in independent 465 
studies. In addition to disease detection and prognosis, the use of these panels is predicted 466 
to be beneficial in several stages of the drug discovery process:  467 
I. Biomarker panels can guide selection of the optimal preclinical models, based on the 468 
similarity with human disease. This will improve the translatability of observations of 469 
effects of new drugs in preclinical models and at this early stage determine safety or 470 
toxicity of the new drug.  471 
II. When moving to the clinical phase these biomarker panels can stratify/identify 472 
patient at risk of progression and thus significantly reduce the number of patients 473 
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required to be included in trials, whilst at the same time increasing the power of the 474 
study, as a result of a much higher number of investigable endpoints.  475 
III. In addition, safety and toxicity can be addressed at an early stage by screening a 476 
number of biomarker panels for comorbidities of the disease under study.  477 
IV. Since all CE-MS based biomarker panels have been identified in urine , a body fluid 478 
accessible non-invasively that can be easily resampled, patient adherence to such 479 
surveillance will be high and drug effects can be easily evaluated on-route.  480 
 481 
Future perspective 482 
Although the CE-MS technology has been around for over 15 years, the biomarker panels for 483 
various diseases identified with this technology have generally not been implemented in the 484 
clinics yet. However, due to the growing evidence supporting the added value of biomarker 485 
panels, it is foreseeable that they will soon become a more widely used tool of choice for 486 
early diagnosis, patients’ stratification or drug evaluation.  487 
Early diagnosis based on biomarkers panels will enable earlier clinical intervention, if 488 
possible, and therefore improve the chance of successful therapy, before irreversible 489 
changes to the organ structures take place. The prognostic value of the biomarker panels is 490 
expected to significantly impact on patient stratification, in particular to select the 491 
appropriate clinical trial population. This development will further pave the way towards 492 
personalized medicine. The usage of CE-MS-based urinary biomarker panels, as a surrogate 493 
marker for specific disease stages, will become more widespread in drug evaluation, based 494 
on the huge amount of data sets available for comparison (which is not available for any 495 
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other proteomics technique) and on the fact that urine is an easily accessible source of 496 
information.  497 
CE-MS-based biomarker panels appear to have substantial potential to facilitate/guide drug 498 
development in preclinical stage. The application of orthologous biomarker panels will 499 
improve translatability of the results obtained from animal model-based preclinical research 500 
and thus decrease the number of unsuccessful trials. Taking into consideration all the 501 
advantages the biomarker panels bring to different health sectors, it is plausible that one day 502 
they will not only complement current gold standards, but in some cases, even replace 503 
them, as recently suggested in a slightly provocative article proclaiming urinary proteome 504 
analysis as “liquid kidney biopsy” [2]. 505 
 506 
Executive summary 507 
• Among different proteomic technology platforms, the CE-MS technology has been 508 
shown to be well suited for biomarker research and on the way for 509 
implementation in the clinic.  510 
• Biomarker panels have advantage over single biomarkers in terms of their stability, 511 
amount and quality of the information that they provide, and are therefore well 512 
suited to reflect the state and complexity of biological systems.  513 
• CE-MS identified proteome based biomarker panels allow early diseases diagnosis 514 
and/or prognosis. Thus they can facilitate early therapeutic intervention and/or 515 
can guide patients to introduce life style changes. 516 
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• CE-MS is the only proteomics based technology has been utilized to analyze wide 517 
range of different diseases and to generate data base composed of over 35.000 518 
highly comparable datasets [101]. 519 
• Urinary based proteomic biomarker panels can be implemented in medical research 520 
and practice, as well as in preclinical and clinical stages of drug development.  521 
• Unique humanized biomarker panels developed using CE-MS carry advantage of 522 
enhancing the translatability of the results obtained in animal models to the 523 
clinic. They minimize the need for usage and sacrifice of experimental animals in 524 
preclinical research and enable longitudinal studies. 525 
• The benefits of implementation of CE-MS identified proteome based biomarker 526 
panels in the clinics are vivid in the area of:  527 
1. patient stratification 528 
2. monitoring of disease progression and/or drug effects (including side effects) 529 
3. ensuring patient safety due to possibility of detecting comorbidities 530 
4. collection of statistically relevant results when conducting the trial  531 
5. practicability (non-invasive and less time consuming method for drug effects 532 
evaluation is patient-friendly and cost-effective) 533 
6. improved patient compliance 534 
• Biomarker panels can facilitate the personalized medicine approach by pointing to 535 
the individual differences between patients.  536 
• CE-MS identified proteome based biomarker panels have added value in medical 537 
research/practice and therefore have the potential to outcompete less accurate 538 





Figure Legends 542 
Figure 1. Proteins as sources of information for clinical research and drug development. 543 
Protein biomarkers and specific proteome pattern (lower right) reflect molecular pathways 544 
characteristic for a disease or a healthy state and represent the drug targets. This 545 
information can generally not be obtained from histological assessment (e.g. in tissue 546 
biopsies).  547 




Figure 2. Omics technologies in analogy to a fireplace. Genomics comprises information 552 
about the entire genome, which can be well examined, yet it generally reflects the 553 
“potential” of an individual and remains unchanged during lifetime. In a way, it is analogous 554 
to the logs in a fireplace: logs have the potential to be set on fire under appropriate 555 
circumstances (oxygen, source of heat, dryness of the log etc.). The proteome delivers 556 
information on the current “status” of an organism, which is complex and continuously 557 
responding to various endogenous and exogenous stimuli. It difficult to assess 558 
comprehensively, undergoing constant changes, similarly to the fire in the fireplace. The 559 
action of the proteins results, at least to some degree, in metabolites. In analogy, the 560 
consequence of fire are ashes. Hence, ashes resemble metabolomics, small compounds, 561 
fairly stable, and allowing conclusions on previous action that led to their generation but 562 
generally not a trait that can be directly manipulated (via drugs) to change the strength of 563 





Figure 3. Schematic representation of the CE-MS-based platform and associated data base. 567 
Urinary peptides are injected in the CE and separated in a high-voltage field. The outlet of the 568 
CE is connected to the MS (time of flight (TOF) mass-spectrometer) using an electron spray 569 
interface (ESI) where mass and relative abundance of each peptide is analyzed. Individual 570 
peptide profiles can be compared to any peptide profile in the database either for 571 
classification or extraction of new biomarkers of yet undefined diseases. Adapted with 572 










Figure 4. Content of the human urinary peptide database. To date, the human urinary 581 
peptide data base encompasses over 35 000 independent CE-MS human urine data sets. It 582 
covers a wide range of diseases including cardiovascular, renal and hematological disease and 583 
a large variety of cancers [101]. Adapted with permission from [13]. 584 
 585 
Figure 5. CE-MS biomarker guided patient stratification. In the PRIORITY clinical trial (NCT 586 
02040441), the CE-MS identified biomarker panel CKD273 is implemented for patient 587 
stratification into the high (red box) and low (green box) risk groups for the development of 588 
CKD. The low risk group, which likely will not develop CKD, will not receive any additional 589 
treatment (as this may bring harm, but likely no benefit). The high-risk patients will be 590 
randomized to the therapy with the investigational drug (low dose spironolactone) or 591 
placebo. A total of 3280 patients are included in the study.  592 





Figure 6. Early diagnosis and/or prognosis of diseases improves chances for a better 596 
outcome for the patients. The initiation of molecular processes that result in (chronic) 597 
diseases can be detected based on the decisive molecular changes, using proteomic 598 
technologies, substantially prior to advanced organ damage. This could allow earlier 599 






Table 1 Main proteomic approaches applied in the field of biomarker research. Several 606 
proteomics platforms can be employed at different stages during the biomarker 607 
development, including discovery (2DE, LC-MS, CE-MS) and validation/ implementation 608 
phase (CE-MS, MRM).  609 
Adapted with permission from [8]. 610 
Table 2 Biomarker panels discovered and/or verified with CE-MS technology. Biomarker 611 
panels for diagnosis and prognosis of many common as well as rare diseases have been 612 
identified using the CE-MS technology. Most of them are for chronic diseases including renal 613 
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